Clinical Investigation of Hereditary and Acquired Thrombophilic Factors in Patients with Venous and Arterial Thromboembolism

Erzsebet Kovács,1 Zsuzsanna Bereczky,2 Adrienne Kerényi,3 Renáta Laczik,4 Valéria Nagy,5 Dávid Ãgoston Kovács,6 Sándor Kovács,7 György Pfliegler1 1Centre of Rare Diseases, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; 2Division of Clinical Laboratory Science, Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary; 3Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary; 4Division of Angiology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; 5Department of Ophthalmology, University of Debrecen, Debrecen, Hungary; 6Department of Surgery, University of Debrecen, Debrecen, Hungary; 7Department of Research Methodology and Statistics, Institute of Sectoral Economics and Methodology, University of Debrecen, Debrecen, HungaryCorrespondence: Erzsebet Kovács, Centre of Rare Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, Debrecen, H-4032, Hungary, Tel +36 52 255574, Email erzsebetkovacs@med.unideb.huBackground: The clinical relevance of thrombophilic laboratory factors, especially the “mild†ones, and the need for their screening is not generally recommended in venous (VTE) and/or arterial (ATE) thromboembolism.Methods: Our aim was to investigate possible associations between comorbidities and 16 inherited/acquired “severe†and “mild†laboratory thrombophilic factors (detailed in introduction) in patients (n=348) with VTE/ATE without a serious trigger (high-risk surgical intervention, active cancer and/or chemo-radiotherapy). Cases with VTE/ATE were enrolled when the thrombotic event occurred under the age of 40, in case of positive family history, recurrent thromboembolism, idiopathic event or unusual location. Patients without a detailed thrombophilia screening or who suffered from both ATE/VTE were excluded to find potential distinct thrombosis type specific thrombophilic risks. The possible role of “mild†factor accumulation was also ...